Herein, we also demonstrate for the first time that IDO is expressed on CTCs and that IDO+ CTCs and particularly the IDO+/PD-L1- subset may have significant prognostic relevance in patients with NSCLC treated with anti-PD-1 agents. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.